A Comparative Study Of Drug Master File Regulation In Brazil, Malaysia And Russia

The burgeoning pharmaceutical market in Brazil, Russia, and Malaysia presents a compelling opportunity for drug development and access. However, navigating the intricacies of drug registration in these countries requires a thorough understanding of their regulatory frameworks, including Drug Master File (DMF) filing procedures. This research article delves into a comparative analysis of DMF requirements in Brazil, Russia, and Malaysia, exploring similarities and differences in content requirements, submission procedures, and review processes. The aim is to equip pharmaceutical companies with the necessary knowledge to navigate these regulatory landscapes effectively.